Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice

Cellular Immunology

Volumn 240, Issue 2, 2006, Pages 96-106

  Jacob, Jennifer ^a   Radkevich, Olga ^a,b   Forni, Guido ^c   Zielinski, John ^a   Shim, David ^a   Jones, Richard F ^d   Wei, Wei Zen ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TURIN   (Italy)

^d State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

DNA vaccine; Her 2; Neu; Transgenic mice; Tumor vaccine

Indexed keywords

CANCER VACCINE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BREAST TUMOR; CANCER IMMUNIZATION; CANCER INHIBITION; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; IMMUNOLOGICAL TOLERANCE; MAMMARY GLAND; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; ANTIBODY FORMATION; ANTIGENS; CANCER VACCINES; CELL LINE, TUMOR; CROSS REACTIONS; FEMALE; HUMANS; IMMUNE TOLERANCE; INTERFERON TYPE II; INTERFERON-GAMMA; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; RATS; RECEPTOR, ERBB-2; T-LYMPHOCYTES; VACCINES, DNA;

MUS MUSCULUS;

EID: 33748468743     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2006.07.002     Document Type: Article

References (34)

1. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., and Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
2. Sjogren S., Inganas M., Lindgren A., Holmberg L., and Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J. Clin. Oncol. 16 (1998) 462-469
3. Wei W.Z., Shi W.P., Galy A., Lichlyter D., Hernandez S., Groner B., Heilbrun L., and Jones R.F. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int. J. Cancer 81 (1999) 748-754
4. Kiessling R., Wei W.Z., Herrmann F., Lindencrona J.A., Choudhury A., Kono K., and Seliger B. Cellular immunity to the Her-2/neu protooncogene. Adv. Cancer Res. 85 (2002) 101-144
5. Disis M.L., Gooley T.A., Rinn K., Davis D., Piepkorn M., Cheever M.A., Knutson K.L., and Schiffman K. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20 (2002) 2624-2632
6. McNeel D.G., Knutson K.L., Schiffman K., Davis D.R., Caron D., and Disis M.L. Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. J. Clin. Immunol. 23 (2003) 62-72
7. + T cell tolerance to an endogenous tumor antigen. J. Immunol. 176 (2006) 974-983
8. + T cells whether or not they are silenced for invariant chain. Cancer Res. 66 (2006) 1147-1154
9. Cuadros C., Dominguez A.L., Lollini P.L., Croft M., Mittler R.S., Borgstrom P., and Lustgarten J. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int. J. Cancer 116 (2005) 934-943
10. Piechocki M.P., Ho Y.S., Pilon S., and Wei W.Z. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J. Immunol. 171 (2003) 5787-5794
11. Lucchini F., Sacco M.G., Hu N., Villa A., Brown J., Cesano L., Mangiarini L., Rindi G., Kindl S., and Sessa F. Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTV-Neu transgenic mice. Cancer Lett. 64 (1992) 203-209
12. Boggio K., Nicoletti G., Di C.E., Cavallo F., Landuzzi L., Melani C., Giovarelli M., Rossi I., Nanni P., De G.C., Bouchard P., Wolf S., Modesti A., Musiani P., Lollini P.L., Colombo M.P., and Forni G. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J. Exp. Med. 188 (1998) 589-596
13. Pupa S.M., Iezzi M., Di C.E., Invernizzi A., Cavallo F., Meazza R., Comes A., Ferrini S., Musiani P., and Menard S. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res. 65 (2005) 1071-1078
14. Oldstone M.B. Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept. Curr. Top. Microbiol. Immunol. 296 (2005) 1-17
15. Miller S.D., and Karpus W.J. The immunopathogenesis and regulation of T-cell-mediated demyelinating diseases. Immunol. Today 15 (1994) 356-361
16. Swanborg R.H., and Stepaniak J.A. Experimental autoimmune encephalomyelitis in the rat. In: Coligan J.E., Kruisbeek A.M., and Margulies D.H. (Eds). Current Protocols in Immunology (1996), John Wiley, New York 15.2.1-15.2.14
17. Myers L.K., Rosloniec E.F., Cremer M.A., and Kang A.H. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci. 61 (1997) 1861-1878
18. Christadoss P., Poussin M., and Deng C. Animal models of myasthenia gravis. Clin. Immunol. 94 (2000) 75-87
19. Bowne W.B., Srinivasan R., Wolchok J.D., Hawkins W.G., Blachere N.E., Dyall R., Lewis J.J., and Houghton A.N. Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med. 190 (1999) 1717-1722
20. Gold J.S., Ferrone C.R., Guevara-Patino J.A., Hawkins W.G., Dyall R., Engelhorn M.E., Wolchok J.D., Lewis J.J., and Houghton A.N. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J. Immunol. 170 (2003) 5188-5194
21. Mahoney K.H., Miller B.E., and Heppner G.H. FACS quantitation of leucine aminopeptidase and acid phosphatase on tumor-associated macrophages from metastatic and nonmetastatic mouse mammary tumors. J. Leukoc. Biol. 38 (1985) 573-585
22. Rovero S., Amici A., Carlo E.D., Bei R., Nanni P., Quaglino E., Porcedda P., Boggio K., Smorlesi A., Lollini P.L., Landuzzi L., Colombo M.P., Giovarelli M., Musiani P., and Forni G. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol. 165 (2000) 5133-5142
23. Nanni P., Pupa S.M., Nicoletti G., De G.C., Landuzzi L., Rossi I., Astolfi A., Ricci C., De V.R., Invernizzi A.M., Di C.E., Musiani P., Forni G., Menard S., and Lollini P.L. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int. J. Cancer 87 (2000) 186-194
24. + regulatory T cell-depleted mice. Cancer Res. 65 (2005) 8471-8478
25. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., and Wu T.C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56 (1996) 21-26
26. Gallo P., Dharmapuri S., Nuzzo M., Maldini D., Iezzi M., Cavallo F., Musiani P., Forni G., and Monaci P. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int. J. Cancer 113 (2005) 67-77
27. Piechocki M.P., Pilon S.A., and Wei W.Z. Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J. Immunol. Methods 259 (2002) 33-42
28. Piechocki M.P., Pilon S.A., and Wei W.Z. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J. Immunol. 167 (2001) 3367-3374
29. Pilon S.A., Kelly C., and Wei W.Z. Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor. J. Immunol. 170 (2003) 1202-1208
30. + Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J. Immunol. 174 (2005) 4228-4236
31. Reilly R.T., Gottlieb M.B., Ercolini A.M., Machiels J.P., Kane C.E., Okoye F.I., Muller W.J., Dixon K.H., and Jaffee E.M. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 60 (2000) 3569-3576
32. + T-cell repertoire. Cancer Res. 65 (2005) 6443-6449
33. Nagata Y., Furugen R., Hiasa A., Ikeda H., Ohta N., Furukawa K., Nakamura H., Furukawa K., Kanematsu T., and Shiku H. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J. Immunol. 159 (1997) 1336-1343
34. Tegerstedt K., Lindencrona J.A., Curcio C., Andreasson K., Tullus C., Forni G., Dalianis T., Kiessling R., and Ramqvist T. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res. 65 (2005) 5953-5957